drug adverse effects of P2Y12 receptor inhibitor(s)
Jump to navigation
Jump to search
Adverse effects
- prasugrel & ticagrelor more potent antiplatelet agents than clopidogrel & superior in preventing ischemic events, at the cost of increased risk of bleeding[1]
- genetic testing may provide some information on risk of bleeding[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Susman E. Genetic Testing Aids in Anticoagulant Selection in ACS. Personalized approach tied to clinically meaningful reduction in ischemic and bleeding events. MedPage Today. March 12, 2018 https://www.medpagetoday.com/meetingcoverage/acc/71722
Ardissino D, et al A prospective, randomised, multicentre study of a pharmacogenomic approach to the selection of antiplatelet therapy in acute coronary syndromes. American College of Cardiology (ACC) 2018; Abstract 18-LB-18910-ACC.
Notarangelo FM, Maglietta G, Bevilacqua P, et al Pharmacogenomic approach to selecting antiplatelet therapy in acute coronary syndromes: PHARMCLO trial. J Am Coll Cardiol. March 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29540324 <Internet> http://www.onlinejacc.org/content/early/2018/02/23/j.jacc.2018.02.029